Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Reward and immune responses in adolescent females following experimental traumatic brain injury.

Cannella LA, Andrews AM, Razmpour R, McGary H, Corbett CB, Kahn J, Ramirez SH.

Behav Brain Res. 2020 Feb 3;379:112333. doi: 10.1016/j.bbr.2019.112333. Epub 2019 Nov 1.

PMID:
31682867
2.

Experimental Traumatic Brain Injury during Adolescence Enhances Cocaine Rewarding Efficacy and Dysregulates Dopamine and Neuroimmune Systems in Brain Reward Substrates.

Cannella LA, Andrews AM, Tran F, Razmpour R, McGary H, Collie C, Tsegaye T, Maynard M, Kaufman MJ, Rawls SM, Ramirez SH.

J Neurotrauma. 2020 Jan 1;37(1):27-42. doi: 10.1089/neu.2019.6472. Epub 2019 Aug 21.

PMID:
31347447
3.

Long-term follow-up of a trial comparing post-remission treatment with autologous or allogeneic bone marrow transplantation or intensive chemotherapy in younger acute myeloid leukemia patients.

Baron F, Efficace F, Cannella L, Willemze R, Vignetti M, Muus P, Marie JP, Ferrero D, Fazi P, La Sala E, Bourhis JH, Fabbiano F, Bosi A, Sborgia M, Martinelli G, Wittnebel S, Trisolini S, Petti MC, Halkes CJM, van der Velden WJFM, de Witte T, Amadori S, Zittoun RA, Suciu S.

Haematologica. 2020 Jan;105(1):e13-e16. doi: 10.3324/haematol.2019.221333. Epub 2019 May 16. No abstract available.

4.

Brain interrupted: Early life traumatic brain injury and addiction vulnerability.

Cannella LA, McGary H, Ramirez SH.

Exp Neurol. 2019 Jul;317:191-201. doi: 10.1016/j.expneurol.2019.03.003. Epub 2019 Mar 9. Review.

PMID:
30862466
5.

How should we assess patient-reported outcomes in the onco-hematology clinic?

Cannella L, Efficace F, Giesinger J.

Curr Opin Support Palliat Care. 2018 Dec;12(4):522-529. doi: 10.1097/SPC.0000000000000386. Review.

PMID:
30239387
6.

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol.

Efficace F, Boccadoro M, Palumbo A, Petrucci MT, Cottone F, Cannella L, Zamagni E, Niscola P, Kyriakou C, Caravita T, Offidani M, Mandelli F, Cavo M.

Health Qual Life Outcomes. 2018 Jun 18;16(1):127. doi: 10.1186/s12955-018-0953-4.

7.

Long-term survival in a patient with metastatic squamous cell lung carcinoma: A case report.

Barletta E, Federico P, Tinessa V, Germano D, Cannella L, Pironti T, Daniele B.

Mol Clin Oncol. 2017 Nov;7(5):928-930. doi: 10.3892/mco.2017.1408. Epub 2017 Sep 1.

8.

Physicians' attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients.

Breccia M, Baccarani M, Rosti G, Cottone F, Cannella L, Guilhot F, Vignetti M, Efficace F.

Health Qual Life Outcomes. 2017 Oct 18;15(1):204. doi: 10.1186/s12955-017-0788-4.

9.

Dexamethasone Attenuates the Enhanced Rewarding Effects of Cocaine Following Experimental Traumatic Brain Injury.

Merkel SF, Andrews AM, Lutton EM, Razmpour R, Cannella LA, Ramirez SH.

Cell Transplant. 2017 Jul;26(7):1178-1192. doi: 10.1177/0963689717714341.

10.

Acute administration of catalase targeted to ICAM-1 attenuates neuropathology in experimental traumatic brain injury.

Lutton EM, Razmpour R, Andrews AM, Cannella LA, Son YJ, Shuvaev VV, Muzykantov VR, Ramirez SH.

Sci Rep. 2017 Jun 19;7(1):3846. doi: 10.1038/s41598-017-03309-4.

11.

Characterization of human fetal brain endothelial cells reveals barrier properties suitable for in vitro modeling of the BBB with syngenic co-cultures.

Andrews AM, Lutton EM, Cannella LA, Reichenbach N, Razmpour R, Seasock MJ, Kaspin SJ, Merkel SF, Langford D, Persidsky Y, Ramirez SH.

J Cereb Blood Flow Metab. 2018 May;38(5):888-903. doi: 10.1177/0271678X17708690. Epub 2017 May 23.

12.

Factors affecting increased risk for substance use disorders following traumatic brain injury: What we can learn from animal models.

Merkel SF, Cannella LA, Razmpour R, Lutton E, Raghupathi R, Rawls SM, Ramirez SH.

Neurosci Biobehav Rev. 2017 Jun;77:209-218. doi: 10.1016/j.neubiorev.2017.03.015. Epub 2017 Mar 28. Review.

13.

Glutamate carboxypeptidase II (GCPII) inhibitor 2-PMPA reduces rewarding effects of the synthetic cathinone MDPV in rats: a role for N-acetylaspartylglutamate (NAAG).

Hicks C, Gregg RA, Nayak SU, Cannella LA, Schena GJ, Tallarida CS, Reitz AB, Smith GR, Rawls SM.

Psychopharmacology (Berl). 2017 Jun;234(11):1671-1681. doi: 10.1007/s00213-017-4568-y. Epub 2017 Mar 1.

14.

Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial.

Daniele G, Lorusso D, Scambia G, Cecere SC, Nicoletto MO, Breda E, Colombo N, Artioli G, Cannella L, Lo Re G, Raspagliesi F, Maltese G, Salutari V, Ferrandina G, Greggi S, Baldoni A, Bergamini A, Piccirillo MC, Tognon G, Floriani I, Signoriello S, Perrone F, Pignata S.

Gynecol Oncol. 2017 Feb;144(2):256-259. doi: 10.1016/j.ygyno.2016.12.011. Epub 2016 Dec 16.

PMID:
27993479
15.

The value of quality of life assessment in chronic myeloid leukemia patients receiving tyrosine kinase inhibitors.

Efficace F, Cannella L.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):170-179. Review.

16.

Pushing the boundaries of care in myelodysplastic syndromes: Physical exercise to improve fatigue and health-related quality of life outcomes.

Efficace F, Cannella L, Cottone F.

Leuk Res. 2016 Oct;49:36-7. doi: 10.1016/j.leukres.2016.08.003. Epub 2016 Aug 9. No abstract available.

PMID:
27526406
17.

The influence of sleep on emotional and cognitive processing is primarily trait- (but not state-) dependent.

Lerner I, Lupkin SM, Corter JE, Peters SE, Cannella LA, Gluck MA.

Neurobiol Learn Mem. 2016 Oct;134 Pt B:275-86. doi: 10.1016/j.nlm.2016.07.032. Epub 2016 Jul 29.

PMID:
27481220
18.

Adolescent Traumatic Brain Injury Induces Chronic Mesolimbic Neuroinflammation with Concurrent Enhancement in the Rewarding Effects of Cocaine in Mice during Adulthood.

Merkel SF, Razmpour R, Lutton EM, Tallarida CS, Heldt NA, Cannella LA, Persidsky Y, Rawls SM, Ramirez SH.

J Neurotrauma. 2017 Jan 1;34(1):165-181. doi: 10.1089/neu.2015.4275. Epub 2016 Jun 7.

19.

Molecular investigation of coexistent chronic myeloid leukaemia and peripheral T-cell lymphoma - a case report.

Gruszka AM, Rabascio C, Cannella L, Sammassimo S, Andreola G, Gregato G, Faretta M, Calleri A, De Molfetta R, Pruneri G, Bertolini F, Alcalay M.

Sci Rep. 2015 Oct 6;5:14829. doi: 10.1038/srep14829.

20.

Health-related quality of life and symptom assessment in randomized controlled trials of patients with leukemia and myelodysplastic syndromes: What have we learned?

Cannella L, Caocci G, Jacobs M, Vignetti M, Mandelli F, Efficace F.

Crit Rev Oncol Hematol. 2015 Dec;96(3):542-54. doi: 10.1016/j.critrevonc.2015.07.012. Epub 2015 Aug 1. Review.

PMID:
26324461
21.

Endothelial progenitor cells in ischemic stroke: an exploration from hypothesis to therapy.

Li YF, Ren LN, Guo G, Cannella LA, Chernaya V, Samuel S, Liu SX, Wang H, Yang XF.

J Hematol Oncol. 2015 Apr 11;8:33. doi: 10.1186/s13045-015-0130-8. Review.

22.

Patient-reported outcomes for the myelodysplastic syndromes: a new MDS-specific measure of quality of life.

Abel GA, Klaassen R, Lee SJ, Young NL, Cannella L, Steensma DP, Efficace F.

Blood. 2014 Jan 16;123(3):451-2. doi: 10.1182/blood-2013-11-540021. No abstract available.

PMID:
24434998
23.

Medical treatment of hepatocellular carcinoma.

Germano D, Tinessa V, Barletta E, Cannella L, Daniele B.

Minerva Med. 2013 Oct;104(5):545-61. Review.

PMID:
24101112
24.

Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.

Germano D, Tinessa V, Barletta E, Cannella L, Daniele B.

Drugs Aging. 2013 Nov;30(11):887-92. doi: 10.1007/s40266-013-0124-6. Review.

PMID:
24097332
25.

Enhanced and aberrant T cell trafficking following total body irradiation: a gateway to graft-versus-host disease?

Vianello F, Cannella L, Coe D, Chai JG, Golshayan D, Marelli-Berg FM, Dazzi F.

Br J Haematol. 2013 Sep;162(6):808-18. doi: 10.1111/bjh.12472. Epub 2013 Jul 15.

PMID:
23855835
26.

Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up.

Pignata S, Cannella L, Leopardo D, Bruni GS, Facchini G, Pisano C.

Ann Oncol. 2011 Dec;22 Suppl 8:viii40-viii44. doi: 10.1093/annonc/mdr470.

PMID:
22180398
27.

Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

Breccia M, Loglisci G, Cannella L, Finsinger P, Mancini M, Serrao A, Santopietro M, Salaroli A, Alimena G.

Leuk Lymphoma. 2012 May;53(5):985-6. doi: 10.3109/10428194.2011.643408. Epub 2012 Jan 11. No abstract available.

PMID:
22112007
28.

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy.

Pignata S, Amant F, Scambia G, Sorio R, Breda E, Rasch W, Hernes K, Pisano C, Leunen K, Lorusso D, Cannella L, Vergote I.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1347-53. doi: 10.1007/s00280-011-1735-4. Epub 2011 Sep 10.

PMID:
21909644
29.

Trisomy 8 in Philadelphia chromosome negative cell preceding the evolution of a Philadelphia chromosome positive clone with the same additional change during imatinib treatment: revisiting the role of genetic instability in chronic myeloid leukemia.

Cannella L, Loglisci G, Nanni M, De Cuia MR, Colafigli G, Salaroli A, Serrao A, Alimena G, Breccia M.

Leuk Lymphoma. 2012 Mar;53(3):497-8. doi: 10.3109/10428194.2011.615425. Epub 2011 Sep 29. No abstract available.

PMID:
21854086
30.

Nilotinib therapy does not induce consistent modifications of cholesterol metabolism resulting in clinical consequences.

Breccia M, Loglisci G, Cannella L, Serrao A, Colafigli G, Salaroli A, Alimena G.

Leuk Res. 2011 Nov;35(11):e215-6. doi: 10.1016/j.leukres.2011.07.026. Epub 2011 Aug 15. No abstract available.

PMID:
21840598
31.

Very short-term lenalidomide treatment associated with durable resolution of anemia in a patient with myelodysplastic syndrome with chromosome 5q deletion.

Cannella L, Latagliata R, Breccia M, Carmosino I, Loglisci G, Volpicelli P, Ferretti A, Santopietro M, Vozella F, Girmenia C, Cuzzola M, Oliva EN, Alimena G.

Ann Hematol. 2012 Feb;91(2):309-10. doi: 10.1007/s00277-011-1263-7. Epub 2011 May 28. No abstract available.

PMID:
21625998
32.

Familial occurrence of myelodysplastic syndrome with del(5q).

Volpicelli P, Latagliata R, Carmosino I, Breccia M, Vozella F, Mancini M, Cannella L, Alimena G.

Leuk Lymphoma. 2011 Jun;52(6):1143-5. doi: 10.3109/10428194.2011.559669. No abstract available.

PMID:
21599595
33.

Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.

Loglisci G, Breccia M, Nanni M, Mancini M, De Cuia R, Cannella L, Salaroli A, Federico V, Serrao A, Loglisci MG, Santopietro M, Alimena G.

Leuk Lymphoma. 2011 Jul;52(7):1372-5. doi: 10.3109/10428194.2011.565394. Epub 2011 Apr 4. No abstract available.

PMID:
21463110
34.

Unexpected erythroid and cytogenetic responses after discontinuation of a short course of lenalidomide as a result of severe skin rash in a patient with 5q syndrome.

Breccia M, Cannella L, Latagliata R, Loglisci G, Salaroli A, Santopietro M, Oliva EN, Alimena G.

J Clin Oncol. 2011 May 10;29(14):e402-3. doi: 10.1200/JCO.2010.33.5083. Epub 2011 Feb 28. No abstract available.

PMID:
21357784
35.

Chemotherapy in epithelial ovarian cancer.

Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G.

Cancer Lett. 2011 Apr 28;303(2):73-83. doi: 10.1016/j.canlet.2011.01.026. Epub 2011 Feb 24. Review.

PMID:
21353386
36.

Isolated central nervous system relapse after nine years of complete molecular remission in a lymphoid blast crisis of chronic myeloid leukemia treated with imatinib.

Breccia M, Santopietro M, Cannella L, Federico V, Loglisci G, Serrao A, Petrucci L, Salaroli A, Nanni M, De Propris MS, Diverio D, Alimena G.

Leuk Res. 2011 Jun;35(6):e91-2. doi: 10.1016/j.leukres.2011.01.026. Epub 2011 Feb 11. No abstract available.

PMID:
21316103
37.

5'-azacitidine in myelodysplastic syndromes with inversion of chromosome 3.

Breccia M, Cannella L, Santopietro M, Loglisci G, Federico V, Salaroli A, Nanni M, Mancini M, Alimena G.

Leukemia. 2011 Apr;25(4):736-7. doi: 10.1038/leu.2011.6. Epub 2011 Feb 4. No abstract available.

PMID:
21293489
38.

Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.

Breccia M, Cannella L, Latagliata R, Nanni M, Santopietro M, Loglisci G, Ferretti A, Barzotti R, Oliva EN, Alimena G.

Leuk Res. 2011 Jun;35(6):e69-70. doi: 10.1016/j.leukres.2010.12.019. Epub 2011 Jan 12. No abstract available.

PMID:
21232796
39.

Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer.

Carlomagno C, Pepe S, D'Armiento FP, D'Armiento M, Cannella L, De Stefano A, Crispo A, Giordano M, De Placido S.

Oncology. 2010;78(5-6):369-75. doi: 10.1159/000320464. Epub 2010 Aug 26.

PMID:
20798559
40.

"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.

Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M, Stefanizzi C, Volpicelli P, Vozella F, Alimena G.

Leuk Res. 2010 Nov;34(11):1472-5. doi: 10.1016/j.leukres.2010.07.001. Epub 2010 Aug 13.

PMID:
20708799
41.

Deferasirox treatment interruption in a transfusion-requiring myelodysplastic patient led to loss of erythroid response.

Breccia M, Loglisci G, Salaroli A, Cannella L, Santopietro M, Alimena G.

Acta Haematol. 2010;124(1):46-8. doi: 10.1159/000314961. Epub 2010 Jul 9. No abstract available.

PMID:
20616538
42.

Evaluation of comorbidities at diagnosis predicts outcome in myelodysplastic syndrome patients.

Breccia M, Federico V, Latagliata R, Mercanti C, D'Elia GM, Cannella L, Loglisci G, Salaroli A, Santopietro M, Alimena G.

Leuk Res. 2011 Feb;35(2):159-62. doi: 10.1016/j.leukres.2010.06.005. Epub 2010 Jul 1.

PMID:
20594593
43.

Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors.

Carlomagno C, Matano E, Bianco R, Cimminiello C, Prudente A, Pagliarulo C, Crispo A, Cannella L, DE Stefano A, D'Armiento FP, DE Placido S.

Exp Ther Med. 2010 Jul;1(4):611-617. Epub 2010 Jul 1.

44.

Concomitant use of imatinib and warfarin in chronic phase chronic myeloid leukemia patients does not interfere with drug efficacy.

Breccia M, Santopietro M, Loglisci G, Stagno F, Cannella L, Carmosino I, Alimena G.

Leuk Res. 2010 Aug;34(8):e224-5. doi: 10.1016/j.leukres.2010.03.015. Epub 2010 Mar 30. No abstract available.

PMID:
20356624
45.

Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance.

Breccia M, Bocchia M, Cannella L, Defina M, Ippoliti M, Loglisci G, Santopietro M, Lauria F, Alimena G.

Br J Haematol. 2010 Jul;150(2):240-2. doi: 10.1111/j.1365-2141.2010.08187.x. Epub 2010 Mar 19. No abstract available.

PMID:
20346015
46.

Imatinib dose escalation in 74 failure or suboptimal response chronic myeloid leukaemia patients at 3-year follow-up.

Breccia M, Stagno F, Vigneri P, Latagliata R, Cannella L, Del Fabro V, Di Raimondo F, Alimena G.

Am J Hematol. 2010 May;85(5):375-7. doi: 10.1002/ajh.21680. No abstract available.

47.

Refractory cytopenia with unilineage dysplasia: analysis of prognostic factors and survival in 126 patients.

Breccia M, Latagliata R, Cannella L, Carmosino I, Santopietro M, Loglisci G, Federico V, Alimena G.

Leuk Lymphoma. 2010 May;51(5):783-8. doi: 10.3109/10428191003682759.

PMID:
20302387
48.

Safety and efficacy of nilotinib in chronic phase chronic myeloid leukemia in a patient with Wolf-Parkinson-White disease and hematological resistance after suboptimal response to imatinib at six months.

Cannella L, Breccia M, Loglisci G, Federico V, Santopietro M, Alimena G.

Acta Oncol. 2010 Apr;49(3):399-400. doi: 10.3109/02841860903521129. No abstract available.

PMID:
20105089
49.

Modifications of fasting glucose values as first sign of resistance in chronic myeloid leukemia chronic phase patients during imatinib treatment.

Breccia M, Muscaritoli M, Cannella L, Loglisci G, Santopietro M, Alimena G.

Leuk Res. 2010 May;34(5):e122-4. doi: 10.1016/j.leukres.2009.11.021. Epub 2009 Dec 16. No abstract available.

PMID:
20018374
50.

Early hemorrhagic death before starting therapy in acute promyelocytic leukemia: association with high WBC count, late diagnosis and delayed treatment initiation.

Breccia M, Latagliata R, Cannella L, Minotti C, Meloni G, Lo-Coco F.

Haematologica. 2010 May;95(5):853-4. doi: 10.3324/haematol.2009.017962. Epub 2009 Dec 16. No abstract available.

Supplemental Content

Loading ...
Support Center